Yahoo India Web Search

Search results

  1. Sales Team Activity Report (STAR) Daily Call Report (DCR) Version 1.0 Build April-2010

  2. Already Customer?

  3. Ajanta Pharma is a specialty pharmaceutical company providing quality medicines across 30+ countries in the world. We enjoy leadership in multiple molecules and therapeutic segments through 1 st to Market products. Learn More. Business Areas. Differentiated & Smart Product Portfolio.

  4. Ajanta holds a unique position having 73% business contribution from Branded Generics, and especially getting it from diversified 30+ countries i.e., India, rest of Asia and Africa.

  5. Ajanta Pharma Limited, also known by the acronym APL, is a multinational company based in India engaged in development, manufacturing, and marketing of pharmaceutical formulations.

  6. Ajanta Pharma at a Glance Renowned Branded Generics Pharma Company We are a well-diversified pharma Company, with a strong presence in chronic-focused Branded Generics businesses across India, Africa, and Asia. Our success is fuelled by our strategy to launch differentiated products for the

  7. Ajanta Pharma Ltd | 130,641 followers on LinkedIn. Serving Health Care Needs Worldwide | Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India. It has...

  8. Get the latest Ajanta Pharma Ltd (AJANTPHARM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

  9. The reaffirmation of the ratings assigned to the bank facilities of Ajanta Pharma Limited (APL) continues to derive strength from strong business profile with focus on specialty therapeutic segments, diversified geographic and product profile, healthy

  10. Ajanta Pharma Ltd. ₹ 2,239 -0.77% 02 Jul - close price. Export to Excel. Follow. ajantapharma.com BSE: 532331 NSE: AJANTPHARM. About. Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages. (Source : 202003-01 Annual Report Page No:70). Key Points.